[Experience in the Use of Tofacitinib in the Treatment of Ulcerative Colitis in Two Pediatric Patients: Two Case Reports].

Introduction: . In this report, the experience using tofacitinib in two pediatric patients diagnosed with ulcerative colitis at the International Hospital of Colombia is described. A review of the current state of the art is also carried out. Cases: . Both patients had already undergone conventional management without an adequate response for almost two years. In case 1, clinical remission was achieved one month after initiating sustained treatment with tofacitinib. In case 2, clinical and endoscopic remissions were achieved two months after initiating treatment. Discussion: . Studies have demonstrated its efficacy as induction and maintenance therapy for moderate to severe active ulcerative colitis, with an acceptable safety profile. However, information about the use of tofacitinib within the treatment arsenal is limited in the pediatric age group. Conclusion: . Tofacitinib is a promising alternative for the treatment of ulcerative colitis with no response or loss of response to conventional treatment. We present the experience of two adolescent patients in whom clinical remission of the disease was achieved earlier than expected, also documenting endoscopic and histologic remission in one of them.